<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recently, mutations in the transcription factor CCAAT/ enhancer binding protein alpha (C/EBPalpha) have been described in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We performed a mutational analysis of the C/EBPalpha gene in the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with antecedent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>No mutations were found in patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (0/27), <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (0/7), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> 0/16) or <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> 0/5) </plain></SENT>
<SENT sid="3" pm="."><plain>One out of 13 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> secondary to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> showed a mutation in the C/EBPalpha gene </plain></SENT>
<SENT sid="4" pm="."><plain>In this patient a 4 bp insertion disrupted codon 69 in one allele </plain></SENT>
<SENT sid="5" pm="."><plain>This novel +1 frame shift is predicted to result in a truncated protein of 107 amino acids </plain></SENT>
<SENT sid="6" pm="."><plain>However, the dominant protein translated was the C/EBPalpha isoform p30, which was previously shown to inhibit the DNA-binding and transactivation properties of C/EBPalpha p42 </plain></SENT>
<SENT sid="7" pm="."><plain>Interestingly this mutation could not be detected at diagnosis in the initial <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> stage </plain></SENT>
<SENT sid="8" pm="."><plain>The mutation appeared at relapse after chemotherapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that the C/EBPalpha mutation was not essential for the initial blast accumulation </plain></SENT>
<SENT sid="10" pm="."><plain>The emergence of a bast clone carrying a C/EBPalpha mutation at relapse indicates that this mutation may confer a growth advantage in a myeloid cell with an established differentiation block </plain></SENT>
</text></document>